The 3^rd ADC Analytical Development Summit is your only industry-dedicated meeting providing you with the key insights to ensure you are developing a high-quality ADC product within regulatory boundaries.

Next year’s program promises to give you even more focused content to better quantify DAR and drug distribution, overcome species separation challenges, and better utilize impurity assays to measure free-linker drug and process-related impurities.

Get an exclusive sneak peek of the agenda here.

Not only is this meeting packed with technical content that will allow you to influence, gain a deeper understanding, and improve product quality, but it will also give you the opportunity to interact with industry experts including:

• Nailing Zhang, Lead Biologist, FDA
• Linda Nelson, Executive Director, RA-CMC, Daiichi Sankyo
• David Lee, Executive Director, Analytical Chemistry, Mersana Therapeutics
• Chris Woods, Scientist, Analytical Development, Seagen
• Madhumati Mukherjee, Senior Scientist, AstraZeneca
• Dengyun (Daisy) Sun, Principal Scientist, Cell Based Sciences, Merck & Co.
• Yan-Hui Liu, Director, Analytical Development, GlaxoSmithKline

…and many more!

See the full speaker lineup and agenda sessions here.

We hope you can join us to network with like-minded colleagues and scientists and have the in-depth technical conversations needed to address the common analytical bottlenecks in ADC development.